Riverside Methodist Hospital Dermatology

Topics

• Contact Dermatitis and Allergies 85
• Cutaneous Melanoma Detection and Management 39
• Dermatology and Skin Diseases 39
• Cutaneous lymphoproliferative disorders research 23
• Nail Diseases and Treatments 16
• Vascular Malformations and Hemangiomas 16
• Nonmelanoma Skin Cancer Studies 15
• Autoimmune and Inflammatory Disorders 12
• Autoimmune Bullous Skin Diseases 12
• Acne and Rosacea Treatments and Effects 11
• Cancer and Skin Lesions 11
• Psoriasis: Treatment and Pathogenesis 10

Most cited

1. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).

   Journal of the American Academy of Dermatology · 2024 · 76 citations · Matthew Zirwas

2. Unmet needs for patients with seborrheic dermatitis.

   Journal of the American Academy of Dermatology · 2024 · 42 citations · Matthew Zirwas

3. Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.

   Journal of the American Academy of Dermatology · 2024 · 36 citations · Matthew Zirwas

4. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.

   JAMA · 2022 · 98 citations · Matthew Zirwas

5. Takotsubo syndrome is a coronary microvascular disease: experimental evidence.

   European heart journal · 2023 · 61 citations · Kelly Kimball

6. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).

   Journal of the American Academy of Dermatology · 2021 · 116 citations ·